SRPT News and Press, Sarepta Therapeutics Inc. From 04/16/24

2024-04-16 12:22:50 ET More on rare disease pharmas/biotechs Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success...

2024-04-11 02:27:54 ET Summary Sarepta Therapeutics reported strong Q4/2023 performance, with $365.1M in net product revenue, up 55% from the previous year. ELEVIDYS, despite not meeting its primary endpoint in the Phase III trial, showed significant improvements in motor function...

2024-04-08 16:11:05 ET Summary Sarepta Therapeutics generated $1.14 billion in revenues in 2023 from its four approved therapies for Duchenne Muscular Dystrophy. The company's gene therapy drug Elevidys faced concerns after a failed confirmatory study, causing a sharp market sell-...

2024-04-06 08:45:00 ET The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure for all illnesses. Further, biotechs often deliver better-than-average...

2024-04-01 10:17:11 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid William Blair starts Solid Biosciences at outperform Piper Sandler upgrades Solid Biosciences to overweight Seeking Alpha’s Quant ...

2024-03-28 13:46:05 ET More on Invesco S&P 500 Equal Weight ETF: RSP: Equal Weighting The S&P 500 To Minimize Magnificent Seven Exposure Is Not Optimal RSP: I Firmly Believe In An Allocation To Equal-Weight At This Juncture RSP: Happy 2024! Don't Make Decisio...

2024-03-20 12:11:15 ET More on Kyowa Kirin Kyowa buyout Orchard wins FDA nod for rare disease therapy Historical earnings data for Kyowa Kirin Dividend scorecard for Kyowa Kirin Financial information for Kyowa Kirin Read the full article on Seeking ...

2024-03-19 10:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-13 16:42:19 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid Solid Biosciences reports Q4 results Solid Biosciences signs agreement with Armatus Bio for AAV-SLB101 Seeking Alpha’s Quant Ratin...

2024-03-13 13:46:03 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamree's Launch Catal...